IHC
Engineered TCR Therapy Demonstrates Durable Responses in Rare Sarcomas
Adaptimmune is advancing regulatory plans for its autologous TCR treatment, afami-cel, for advanced sarcoma based on Phase II trial results.
Akoya Biosciences, AstraZeneca Collaborate on Spatial Biomarker Profiling for Immuno-Oncology
The firms will study drug mechanisms of action, confirm the prevalence of targets, and discover predictive signatures for subsequent trial designs.
FDA Approves Keytruda-Herceptin Combination for HER2-Positive Gastric, Gastroesophageal Cancer
The agency granted accelerated approval to Merck's pembrolizumab plus Herceptin and chemotherapy for patients with advanced, HER2-positive gastric cancer.
Ligand Expression Predicts Vectibix Benefit in Colon Cancer, Roche and U of Leeds Study Says
An artificial intelligence- and IHC-based assay predicted improved benefit with Amgen's panitumumab among patients with high AREG and EREG ligand expression.
FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer
The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.
Jan 22, 2021
Aug 25, 2020
Oct 31, 2019